evolocmab作为lorlatinib继发性血脂异常的治疗

Clínica e Investigación en Arteriosclerosis (English Edition) Pub Date : 2023-03-01 DOI:10.1016/j.artere.2023.05.003

Laura Pérez Alonso , Raquel Cervera Calero , María Ángeles Campos Fernández de Sevilla , Miguel Ángel Moreno Palanco , Jorge Francisco Gómez Cerezo

{"title":"evolocmab作为lorlatinib继发性血脂异常的治疗","authors":"Laura Pérez Alonso , Raquel Cervera Calero , María Ángeles Campos Fernández de Sevilla , Miguel Ángel Moreno Palanco , Jorge Francisco Gómez Cerezo","doi":"10.1016/j.artere.2023.05.003","DOIUrl":null,"url":null,"abstract":"<div><p>Anti-PCSK9 monoclonal antibodies have reduced the risk of cardiovascular events in patients with atheroesclerosis cardiovascular disease. However, its use has not been described in hyperlipidemia associated with lorlatinib, a third-generation ALK tyrosin kinasa inhibitor approved as treatment for ALK-positive non-small cell lung cancer.</p></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"35 2","pages":"Pages 88-90"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evolocumab como tratamiento de la dislipemia secundaria a lorlatinib\",\"authors\":\"Laura Pérez Alonso , Raquel Cervera Calero , María Ángeles Campos Fernández de Sevilla , Miguel Ángel Moreno Palanco , Jorge Francisco Gómez Cerezo\",\"doi\":\"10.1016/j.artere.2023.05.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Anti-PCSK9 monoclonal antibodies have reduced the risk of cardiovascular events in patients with atheroesclerosis cardiovascular disease. However, its use has not been described in hyperlipidemia associated with lorlatinib, a third-generation ALK tyrosin kinasa inhibitor approved as treatment for ALK-positive non-small cell lung cancer.</p></div>\",\"PeriodicalId\":100263,\"journal\":{\"name\":\"Clínica e Investigación en Arteriosclerosis (English Edition)\",\"volume\":\"35 2\",\"pages\":\"Pages 88-90\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clínica e Investigación en Arteriosclerosis (English Edition)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2529912323000190\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clínica e Investigación en Arteriosclerosis (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2529912323000190","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

抗PCSK9单克隆抗体降低了动脉粥样硬化性心血管疾病患者发生心血管事件的风险。然而，其在与洛拉替尼相关的高脂血症中的应用尚未得到描述，洛拉替尼是一种第三代ALK酪氨酸kinasa抑制剂，被批准用于治疗ALK阳性非小细胞肺癌癌症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Evolocumab como tratamiento de la dislipemia secundaria a lorlatinib

Anti-PCSK9 monoclonal antibodies have reduced the risk of cardiovascular events in patients with atheroesclerosis cardiovascular disease. However, its use has not been described in hyperlipidemia associated with lorlatinib, a third-generation ALK tyrosin kinasa inhibitor approved as treatment for ALK-positive non-small cell lung cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clínica e Investigación en Arteriosclerosis (English Edition)

自引率

0.00%

发文量